DB:1TT

Stock Analysis Report

Executive Summary

Factor Therapeutics Limited operates as a clinical stage biotechnology company.


Snowflake Analysis

Flawless balance sheet with proven track record.

Share Price & News

How has Factor Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 1TT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0%

1TT

0.4%

DE Biotechs

-0.9%

DE Market


1 Year Return

100.0%

1TT

10.0%

DE Biotechs

12.8%

DE Market

Return vs Industry: 1TT exceeded the German Biotechs industry which returned 10% over the past year.

Return vs Market: 1TT exceeded the German Market which returned 12.8% over the past year.


Shareholder returns

1TTIndustryMarket
7 Day0%0.4%-0.9%
30 Day0%-3.2%-0.4%
90 Day100.0%4.6%2.3%
1 Year100.0%100.0%10.3%10.0%16.3%12.8%
3 Year-94.2%-94.3%49.4%47.8%15.8%5.7%
5 Year-98.5%-98.6%13.9%11.5%19.7%3.3%

Price Volatility Vs. Market

How volatile is Factor Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Factor Therapeutics undervalued compared to its fair value and its price relative to the market?

1.84x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 1TT (€0) is trading above our estimate of fair value (€0)

Significantly Below Fair Value: 1TT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 1TT is good value based on its PE Ratio (1.8x) compared to the Biotechs industry average (39.8x).

PE vs Market: 1TT is good value based on its PE Ratio (1.8x) compared to the German market (21x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 1TT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 1TT is good value based on its PB Ratio (1.1x) compared to the DE Biotechs industry average (3.5x).


Next Steps

Future Growth

How is Factor Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

35.7%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Factor Therapeutics has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Factor Therapeutics performed over the past 5 years?

21.4%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 1TT has high quality earnings.

Growing Profit Margin: 1TT became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: 1TT has become profitable over the past 5 years, growing earnings by 21.4% per year.

Accelerating Growth: 1TT has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: 1TT has become profitable in the last year, making it difficult to compare its past year earnings growth to the Biotechs industry (-4.7%).


Return on Equity

High ROE: 1TT's Return on Equity (57.8%) is considered outstanding.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Factor Therapeutics's financial position?


Financial Position Analysis

Short Term Liabilities: 1TT's short term assets (A$3.1M) exceed its short term liabilities (A$245.1K).

Long Term Liabilities: 1TT has no long term liabilities.


Debt to Equity History and Analysis

Debt Level: 1TT is debt free.

Reducing Debt: 1TT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: 1TT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if 1TT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: 1TT is profitable, therefore cash runway is not a concern.

Forecast Cash Runway: 1TT is profitable, therefore cash runway is not a concern.


Next Steps

Dividend

What is Factor Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate 1TT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate 1TT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if 1TT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if 1TT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 1TT's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average board tenure


CEO

Factor Therapeutics has no CEO, or we have no data on them.


Board Members

NamePositionTenureCompensationOwnership
Cherrell Hirst
Independent Chairman4.8yrsAU$25.55k0.36% A$7.0k
Robert Kirsner
Member of Medical Advisory Board3.5yrsno datano data
John Michailidis
Independent Non Executive Director3yrsAU$21.40k0.051% A$966.6
Keith Harding
Member of Medical Advisory Board3.5yrsno datano data
David Brookes
Non-Executive Director0.8yrsAU$19.16k1.23% A$23.5k
David Margolis
Member of Medical Advisory Board3.5yrsno datano data
Christian Behrenbruch
Independent Non Executive Director4.3yrsAU$21.60k0.31% A$6.0k
Ronald Shannon
Member of Medical Advisory Board0yrsno datano data

3.5yrs

Average Tenure

59yo

Average Age

Experienced Board: 1TT's board of directors are considered experienced (3.5 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 27.3%.


Top Shareholders

Company Information

Factor Therapeutics Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Factor Therapeutics Limited
  • Ticker: 1TT
  • Exchange: DB
  • Founded:
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: AU$3.129m
  • Listing Market Cap: AU$1.911m
  • Shares outstanding: 1.04b
  • Website: https://www.factor-therapeutics.com

Location

  • Factor Therapeutics Limited
  • 10 Eagle Street
  • Level 21
  • Brisbane
  • Queensland
  • 4000
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
FTTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDMar 2004
1TTDB (Deutsche Boerse AG)YesOrdinary SharesDEEURMar 2004
FTTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDMar 2004

Biography

Factor Therapeutics Limited operates as a clinical stage biotechnology company. The company was formerly known as Tissue Therapies Limited and changed its name to Factor Therapeutics Limited in May 2016. Factor Therapeutics Limited is based in Brisbane, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/02/23 22:13
End of Day Share Price2020/02/21 00:00
Earnings2019/12/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.